Zindolin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zindolin

This foundational section defines the medicine Zindolin by its composition, classification, and general function, adhering strictly to the identity-level context.

Property Description
Active ingredient Ciprofloxacin (often as hydrochloride)
Form Tablet, oral/injectable solution, ophthalmic solution
Pharmacological class Fluoroquinolone Antibiotic; Anti-infective agent
General purpose Countering systemic bacterial infections
Origin Synthetic compound

What Type of Anti-infective Medicine is Zindolin?

Zindolin is a potent, synthetic compound whose single active ingredient is Ciprofloxacin, belonging to the specialized Fluoroquinolone antibiotic class. It is broadly categorized as a systemic anti-infective agent whose primary function is to counter harmful bacteria causing illness. Ciprofloxacin's inclusion on recognized essential medicine lists confirms its necessity in a basic health system.

The Ciprofloxacin active ingredient in Zindolin is noted for its broad-spectrum antibacterial activity, meaning the drug is effective against numerous types of bacterial infections across the body. Its highly specific structure enables its use in situations requiring intervention against a diverse array of susceptible organisms.


Zindolin's Composition and Available Forms

The core of the medicine is Ciprofloxacin, often utilized as the salt Ciprofloxacin hydrochloride, prepared for various routes of administration. Zindolin is not limited to one physical format; Ciprofloxacin is available in multiple distinct dosage forms, including the orally administered tablet and oral suspension, the injectable solution for intravenous infusion, and the specialized topical ophthalmic solution.

Zindolin products are typically prescription-only medicine due to the specific nature and potency of the Ciprofloxacin active ingredient. The existence of these multiple pharmaceutical preparations ensures that this potent anti-infective agent can be delivered effectively to the target area, whether absorbed systemically or applied locally to treat conditions like eye infections.


General Purpose: Why Does Ciprofloxacin Kill Bacteria?

The general therapeutic role of Zindolin is to successfully interrupt and resolve systemic bacterial infections by eliminating the responsible organisms. Ciprofloxacin achieves this by exhibiting bactericidal activity, meaning it actively destroys susceptible bacteria rather than simply slowing their growth.

This action involves the Ciprofloxacin entity interfering with essential bacterial genetic machinery, specifically enzymes critical for bacterial DNA replication and survival. By inhibiting these processes, the drug prevents the bacteria from multiplying and ensures the intended powerful antibacterial intervention.

Regulatory References

  1. World Health Organization Model List of Essential Medicines

What side effects are possible with Zindolin?

Official Regulatory Safety Profile and Adverse Effects

The safety profile of Zindolin (Ciprofloxacin), a Fluoroquinolone antibiotic, is characterized by both common adverse reactions and warnings for serious, potentially irreversible systemic effects, as outlined by regulatory authorities. The most frequently documented effects, seen in at least 1% of patients in clinical trials, often involve the Gastrointestinal system (e.g., nausea, diarrhea, abdominal pain) and the Nervous system (e.g., headache, dizziness). Other common reactions include rash and abnormal liver function tests.


Serious Adverse Reactions

Official regulatory documents emphasize the risk of disabling and potentially irreversible adverse reactions that can affect multiple body systems, including the musculoskeletal and nervous systems. These serious risks include tendinitis and tendon rupture (especially the Achilles tendon), peripheral neuropathy (nerve damage in the extremities), and Central Nervous System (CNS) effects (e.g., severe confusion, anxiety, seizures).

Other serious documented effects include Aortic Aneurysm and Dissection, Prolongation of the QT interval (a cardiac rhythm abnormality), Hepatotoxicity (severe liver injury), and Exacerbation of Myasthenia Gravis (due to increased muscle weakness).

Population-Specific and Time-Related Safety

Older adults (typically age ge 60) are documented to be at an increased risk for severe tendon disorders, particularly when taking concomitant corticosteroids. The use of Zindolin is contraindicated in patients with a known history of Myasthenia Gravis. Regulatory information notes that the serious, multi-systemic adverse reactions can occur within hours to weeks of starting treatment, and tendon rupture can manifest months after treatment has been stopped. Official safety constraints mandate reserving this medicine for use only when there are no alternative treatment options for certain, less severe infections.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information for Zindolin

Acute overdosage of Zindolin (Ciprofloxacin) may result in specific clinical manifestations and requires immediate emergency action as strictly defined by regulatory authorities.

Documented Overdose Manifestations

Overdose has been officially documented to affect the Central Nervous System (CNS) and the Renal System. Manifestations may include CNS effects such as dizziness, tremor, confusion, tiredness, and hallucinations, with the potential for seizures (convulsions) in severe cases. Acute overdose is also associated with crystalluria (crystal formation in the urine) and potential reversible renal impairment.

When to Seek Emergency Medical Attention

Regulators mandate that urgent medical attention must be sought immediately for any known or suspected overdose. Immediate contact with emergency services is required, particularly if severe signs of CNS toxicity, such as a seizure or significant change in mental status, are present. No specific antidote is known for Ciprofloxacin overdose.

Official Management Procedures

Management is strictly symptomatic and supportive. Officially described procedures to reduce absorption include gastric lavage or administration of activated charcoal. Maintaining adequate hydration is essential to minimize the risk of crystalluria. Hospital monitoring is required, including observation of renal function and necessary cardiac monitoring.

Therapeutic Uses of Zindolin

What Zindolin Treats: Main Uses and Benefits

The medication is applied in addressing various infectious diseases. This class of medicine is commonly used in the symptomatic management of conditions involving systemic or localized discomfort caused by susceptible bacteria.

Types of Conditions and Symptom Relief

Zindolin is commonly used to help with symptoms associated with acute or episodic changes, including symptoms related to systemic imbalance, symptoms that create noticeable physiological strain, and symptoms that become more disruptive during flare-ups. It is also relevant in contexts marked by increased discomfort or tension, often applied across domains where additional symptomatic support is needed, including symptoms related to physical discomfort or symptoms linked to organ-specific functional stress. The medicine plays a role in managing symptoms that create noticeable physiological strain.


“Applied in scenarios where additional management of discomfort is required, Zindolin may help patients cope more steadily with symptom fluctuations during symptomatic phases.”


Quick Fact: Relief for Symptoms that Interfere with Daily Functioning


Therapeutic Benefit

This medication provides support that helps ease the overall symptom load and contributes to easing the overall symptom load during periods of heightened symptoms. It assists with maintaining functional stability when the underlying condition affects daily routine, helps address symptom clusters that may become intense or disruptive.

Regulatory References

  1. NIH MedlinePlus Drug Information on Ciprofloxacin

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Zindolin — Official Regulatory Information

The use of Zindolin (Ciprofloxacin) is defined by strict regulatory exclusions and conditional guidelines. It is contraindicated in patients with a known hypersensitivity to the drug or any other fluoroquinolone antibiotic, in those with a history of Myasthenia Gravis (due to the risk of exacerbation), and when concurrently administered with Tizanidine.

Eligibility Scope

The medicine is primarily intended for adult patients (18 and older). Use in pediatric patients (under 18) is generally restricted and is only indicated for specific, severe conditions, such as complicated urinary tract infections or post-exposure inhalational anthrax, and must be initiated by specialist physicians. Older adults require special caution due to an increased risk of tendon damage and age-related organ issues.

Pregnancy and lactation are generally non-recommended conditions for treatment with oral or intravenous formulations, as the drug is excreted in human milk.

Eligibility-Related Restrictions

Conditional use is required for several populations. Patients with renal impairment may require conditional use due to slower drug clearance. Use should generally be avoided in individuals with a history of tendon disorder related to previous quinolone treatment or known QT prolongation. Patients who have had an organ transplant also require special caution. Hepatic impairment typically does not require a dose adjustment but necessitates caution.

Connection to the overall eligibility profile

Regulatory documents strictly define who can and cannot use Zindolin by establishing absolute contraindications and then limiting eligibility based on age, organ function, and specific comorbidities, ensuring use remains within officially documented populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Zindolin (Ciprofloxacin) as defined in government regulatory documents.


Interaction Classification Interacting Substances (Examples) Official Regulatory Description
Contraindicated Tizanidine (Skeletal Muscle Relaxant) Co-administration is prohibited due to the resulting significant increase in Tizanidine plasma concentrations.
Pharmacokinetic Theophylline, Caffeine, Clozapine Ciprofloxacin acts as an inhibitor of the CYP1A2 enzyme, which reduces the clearance of these substances, leading to elevated exposure and potential toxicity.
Absorption-Reducing Antacids (containing Magnesium/Aluminum), Iron Salts, Zinc Supplements, Sucralfate These multivalent cation products reduce oral Ciprofloxacin absorption via chelation, significantly lowering its bioavailability.
Pharmacodynamic Warfarin (Anticoagulant), NSAIDs Potentiation of the anticoagulant effect is officially noted. Concomitant use with NSAIDs has been documented to increase the risk of CNS stimulation.

Timing and Separation Rules: Oral Ciprofloxacin must be administered at least two hours before or six hours after the ingestion of multivalent cation-containing products (including certain antacids, mineral supplements, and sucralfate) to mitigate the official absorption-reducing interaction. Dairy products or calcium-fortified beverages consumed alone also require this time separation. The interaction profile notes that co-administration of Probenecid reduces Ciprofloxacin renal clearance, resulting in a documented increase in systemic concentration. Furthermore, the risk of cardiotoxicity from QT prolongation is noted to be of greater concern in the elderly patient population.

Mechanism of Action

Targeted Blockade of Bacterial DNA's Core Machinery

Zindolin's mechanism begins with the inhibition of two critical bacterial enzymes, DNA Gyrase (Topoisomerase II) and Topoisomerase IV. The drug traps these enzymes onto the bacterial DNA, forming a lethal complex that prevents the bacteria from completing essential processes like replication and repair. This targeted action functions to achieve the elimination of the bacterial load by attacking the organism's core genetic stability.

Irreversible DNA Damage and Bactericidal Action

The enzyme blockade leads to the accumulation of widespread and irreversible double-strand DNA breaks throughout the bacterial genome. This massive damage triggers the bacterial SOS response pathway, which, in this context, acts as a self-destruct mechanism. The consequence is a rapid bactericidal effect that leads to the destruction of the susceptible pathogen population.

Constraints on Mechanistic Effectiveness

The drug's effectiveness is constrained by biological counter-mechanisms, primarily bacterial adaptation. These include point mutations in the enzyme binding sites (QRDRs) and the expression of efflux pumps, which actively transport the drug out of the bacterial cell. These constraints reduce the drug's ability to reach its target or successfully bind to it, potentially reducing the degree of bactericidal activity.

Dosage and Administration Information

How Zindolin is Used: Official Administration Guidelines

Zindolin (Ciprofloxacin) is officially administered via several approved routes and forms. For systemic treatment, administration occurs through oral forms (immediate-release or extended-release tablets, suspension) or as an intravenous (IV) infusion. A topical ophthalmic solution is also authorized for localized use.


Dosage and Frequency Patterns

The required dose and schedule are explicitly defined. Adult oral doses typically range from 250 mg to 750 mg per dose and are commonly administered twice daily. Specific regimens, such as those using the extended-release tablet or treating acute uncomplicated cystitis, follow a once daily schedule. For severe infections, the IV dose may reach 400 mg every eight hours.

Treatment duration is not uniform: courses may range from a 3-day short course for certain infections to a 60-day extended regimen for post-exposure prophylaxis.


Procedural Administration Instructions

Zindolin can be taken with or without food. However, proper use strictly requires separating the dose from dairy products and supplements containing multivalent cations (e.g., iron or calcium) by at least two to six hours to ensure adequate absorption.

All extended-release tablets must be swallowed whole and must not be crushed or chewed. IV solutions must be administered as a slow infusion over 60 minutes into a vein. For certain populations, like older adults or patients with renal impairment, dose selection is based on an assessment of the patient’s creatinine clearance.

Recent Clinical Evidence

Research evidence / Overview of studies for Zindolin


Evidence for Systemic and Complicated Bacterial Infections

Zindolin was studied for a range of serious and complicated bacterial infections, such as those in the urinary tract (like pyelonephritis) and deep infections in the bones and joints. The research base for these uses includes Randomized Controlled Trials (RCTs) and systematic reviews. These studies primarily examined two key outcomes: bacteriological eradication (clearance of the bacteria) and clinical success (assessment of the infection's signs and symptoms).

Studies reported measurements of both the clearance of bacteria and the evolution of related clinical findings across the adult populations studied. Research describes how these outcomes were tracked across various adult groups and in some pediatric patients. However, long-term outcomes extending beyond the immediate few weeks after treatment are not fully established.


Evidence for Chronic or Recurrent Respiratory Infections

Research examined Zindolin, often in its specialized inhalable form, in studies focusing on chronic or recurrent infections, particularly in adults with conditions like Non-Cystic Fibrosis Bronchiectasis (NCFB). The studies evaluated patient-reported outcomes describing perceived discomfort and specific outcomes focusing on the frequency of acute pulmonary exacerbations and the time to the first exacerbation. These long-term studies, which used cyclical and intermittent treatment schedules, described patterns observed in the studies over the long observation periods.

Some trials reported measurements of exacerbation frequency in the population studied and the control group. The studies described patterns related to the time to the first pulmonary exacerbation. Certainty remains low for some aspects of this use. There is limited information for long-term outcomes regarding the durability of these patterns after the treatment period ends, and evidence is limited and heterogeneous across various patient subgroups.


What Is Still Uncertain About Zindolin Research

Several areas remain uncertain in the Zindolin research landscape. Evidence quality varies across studies, and the comparative evidence is lacking for some treatment regimens. The largest uncertainty is the long-term impact of emerging antimicrobial resistance. The research is continuing to explore how the medicine functions in these contexts. Additionally, follow-up durations were limited in many core trials, meaning long-term effects are not fully established.

Frequently Asked Questions (FAQ)

Common questions about Zindolin (FAQ)

Q: What is Zindolin used for?

Zindolin is a medication prescribed to manage symptoms associated with specific CNS conditions, such as reducing the frequency of abnormal nerve activity in the brain. It acts by affecting certain chemicals and nerve signals within the brain and is often used alongside other treatments.

Q: How should I take Zindolin?

Always take Zindolin exactly as your healthcare provider instructs. It's usually taken by mouth, with or without food. Do not stop taking it suddenly, even if you feel well, without first discussing it with your prescriber, as this can lead to adverse effects.

Q: What are the possible side effects of Zindolin?

Common side effects may include dizziness, drowsiness, and fatigue, especially when starting treatment. Less common but more serious effects can include changes in mood or behavior. Report any unusual symptoms to your doctor immediately.

Q: Can I drink alcohol while taking Zindolin?

Alcohol consumption should generally be limited or avoided while taking Zindolin. Both Zindolin and alcohol can cause dizziness and drowsiness, and combining them may increase these effects, potentially leading to impaired coordination and poor judgment.

How should Zindolin be stored and disposed of?

How to Store and Dispose of Ciprofloxacin (Zindolin)

Official regulatory guidelines define strict conditions for the storage and disposal of this medicine, identified as Ciprofloxacin, a fluoroquinolone antibiotic.


Storage Requirements

Ciprofloxacin must be stored at Controlled Room Temperature, which is 20 to 25 C (68 to 77 F). The product must be protected from heat, moisture, and direct light, and it is essential not to freeze the medicine. Keep the container tightly closed and store it out of the reach of children.

Stability and Disposal

The reconstituted oral suspension has a strict shelf-life and must be discarded after 14 days from the date of preparation. For disposal of unused or expired medicine, use community drug take-back programs. If a program is unavailable, follow the procedure of mixing the product with an undesirable substance before discarding it in the household trash, as recommended by the FDA.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zindolin found in:

A-Z Index: